Endometriosis
Conditions
Interventions
Healthy control group (non-endometriosis control group):None
Sponsors
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Endometriosis Group 1. Meets Western and Traditional Chinese Medicine diagnostic criteria; dysmenorrhea score <=8 points 2. Aged 20-45 years, premenopausal women, with regular menstrual cycles (23-37 days) 3. Able to provide informed consent 4. Patients with pelvic endometriosis combined with adenomyosis may be included Healthy Control Group 1. Aged 20-45 years 2. Regular menstrual cycles: defined as a cycle length of 21-35 days, with cycle variation <7 days 3. No history of endometriosis 4. Signed informed consent: voluntarily participates in the study and is able to understand and sign the informed consent form
Exclusion criteria
Exclusion criteria: Endometriosis Group 1. Patients planning to undergo surgery in the near future 2. Patients with pelvic infection or other severe gynecological diseases (such as gynecological malignancies) 3. Patients with severe primary diseases involving the cerebrovascular, hepatic, renal, hematopoietic, thyroid systems, or malignancies; patients with psychiatric disorders; patients with epilepsy 4. Serum CA125 >200 U/ml 5. Ovarian endometrioma >5 cm, or accompanied by other types of ovarian cysts or solid masses; uterine fibroids >5 cm 6. Dysmenorrhea caused by other reasons; or any situation deemed by the researcher to affect participant safety Healthy Control Group 1. Current or history of any benign or malignant gynecological tumors: such as uterine fibroids (symptomatic or diameter >3 cm), ovarian cysts (excluding physiological cysts), adenomyosis, cervical lesions, ovarian cancer, etc. 2. Currently pregnant or breastfeeding; postmenopausal status; presence of unexplained pelvic masses or abnormal uterine bleeding 3. Use of hormonal medications within 3-6 months prior to enrollment 4. Severe systemic diseases: uncontrolled endocrine disorders (such as hyper/hypothyroidism, diabetes), autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis), cardiovascular diseases, hepatic or renal insufficiency, etc. 5. Long-term use of anti-inflammatory or analgesic drugs (such as non-steroidal anti-inflammatory drugs, opioids); history of psychiatric disorders or substance abuse 6. Any other situation deemed by the researcher that may affect study assessment or participant safety
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum CA125;Tongue characteristics;Glycometabolism and Lipid Metabolism Related Indicators;Pain Visual Analogue Scale (VAS) Score; | — |
Countries
China
Contacts
Public ContactZheng Weilin
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Outcome results
None listed